This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
3 Dividend-Paying Large Cap Pharma Stocks to Consider for 2020
by Christopher Vargas
The stock market continued its end of the year rally Friday as the three major indices all hit new intraday highs.
The 3 Most Popular Value Investor Podcasts of 2019
by Tracey Ryniec
What tips, screens and stocks were value investors most interested in in 2019? Here are the most popular podcasts of the year.
Merck (MRK) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Merck (MRK) closed the most recent trading day at $91.44, moving -0.33% from the previous trading session.
Biotech Leading in Q4: Best ETFs & Stocks
by Sweta Killa
We highlight five biotech ETFs and stocks that are leading the market in Q4.
ImmunoGen Lead Drug Gets Nod for Accelerated Approval Pathway (Revised)
by Zacks Equity Research
FDA approves a new pivotal study to support accelerated approval pathway for ImmunoGen's (IMGN) ovarian cancer candidate, mirvetuximab soravtansine.
The Zacks Analyst Blog Highlights: Prologis, Best Buy and Merck
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Prologis, Best Buy and Merck
AstraZeneca Gets FDA Nod for New Breast Cancer Drug Enhertu
by Zacks Equity Research
AstraZeneca's (AZN) antibody drug conjugate candidate, Enhertu gets FDA approval for treating HER2-positive breast cancer in third or later-line setting.
Bristol-Myers' Revlimid Combo Gets EU Nod for New Indication
by Zacks Equity Research
The EC approves Bristol-Myers' (BMY) Revlimid in combination with Rituxan for the treatment of previously-treated FL (Grade 1-3a).
3 Income Stocks to Buy with Market at New Highs
by Christopher Vargas
The stock market rose to record highs again on Friday as part of a much longer and historic expansion in the US economy.
Pharma Stock Roundup: Lilly's Upbeat 2020 Outlook, FDA Nod for PFE & MRK's Drugs
by Kinjel Shah
Lilly (LLY) issues upbeat financial guidance for 2020. FDA approves label expansion of Pfizer's (PFE) Xtandi and Merck's (MRK) Ebola vaccine, Ervebo.
Merck's Ebola Vaccine Ervebo Gets Approval in United States
by Zacks Equity Research
FDA grants approval to Merck's (MRK) Ervebo vaccine for active immunization of individuals 18 years and above to protect against Ebola virus disease caused by Zaire Ebola virus.
Seattle Genetics Gets Speedy FDA Nod for Bladder Cancer Drug
by Zacks Equity Research
The FDA grants accelerated nod to Seattle Genetics' (SGEN) Padcev to treat urothelial cancer. It also assigns Breakthrough Therapy tag to tucatinib for advanced/metastatic HER2-positive breast cancer.
Pentair Shuts Down Aquaculture Business, Divests Vaki Unit
by Zacks Equity Research
Pentair (PNR) divests Vaki business unit to focus on the residential and commercial pool segments.
Buy These 5 Stocks With Upgraded Broker Ratings for 2020
by Swayta Shah
When a broker upgrades a stock, you can rely on their judgment. Nonetheless, you should also take into account few other factors to ensure steady returns.
FDA Panel Laps Up Merck's Keytruda & Lynparza for New Maladies
by Zacks Equity Research
The FDA's ODAC votes in favor of Merck's (MRK) Keytruda for non-muscle invasive bladder cancer. The panel also backs Lynparza as a first-line maintenance monotherapy for pancreatic cancer.
ImmunoGen Lead Drug Gets Nod for Accelerated Approval Pathway
by Zacks Equity Research
FDA approves a new pivotal study to support accelerated approval pathway for ImmunoGen's (IMGN) ovarian cancer candidate, mirvetuximab soravtansine. Shares up.
Lilly's Stock Up on Upbeat Sales & Profit Outlook for 2020
by Zacks Equity Research
Eli Lilly's (LLY) stock up on Tuesday after it provides an upbeat financial guidance for the next year.
Novartis' Asthma Candidate Fails in LUSTER Phase III Studies
by Zacks Equity Research
Novartis' (NVS) asthma candidate, fevipiprant, fails to meet endpoint in the phase III LUSTER studies.
Pfizer's Xtandi Gets FDA Nod for Expanded Patient Group
by Zacks Equity Research
With data from the ARCHES study approved to be included in the label of Pfizer's (PFE) Xtandi, it can treat a broader prostate cancer patient population.
Pfizer Gets CHMP Nod for Vyndaqel Label Expansion in Europe
by Zacks Equity Research
Pfizer (PFE) receives a positive CHMP opinion recommending approval for once-daily Vyndaqel (61mg) oral capsule to treat hereditary transthyretin amyloid cardiomyopathy in adult patients.
Roche's (RHHBY) Tecentriq Combo Succeeds in Melanoma Study
by Zacks Equity Research
Roche's (RHHBY) Tecentriq in combination with Cotellic and Zelboraf meets primary goal.
Pharma Stock Roundup: MRK, SNY to Buy Cancer Firms, LLY Starts New Lung Cancer Study
by Kinjel Shah
This week two deals grab headlines in the pharma space. Merck (MRK) offers to buy ArQule for $2.7 billion while Sanofi (SNY) signs a definitive deal to purchase Synthorx for $2.5 billion
AstraZeneca's Imfinzi Gets China Nod for Stage III NSCLC
by Zacks Equity Research
AstraZeneca's (AZN) Imfinzi becomes the first immunotherapy to receive approval in China for treating unresectable, stage III NSCLC, which has not progressed following chemotherapy and radiation therapy.
Sanofi, Regeneron to Amend Agreement for Kevzara & Praulent
by Zacks Equity Research
Sanofi (SNY) intends to amend its antibody collaboration with Regeneron related to Kevzara and Praulent into a royalty-based agreement. Agreement terms for Dupixent to remain intact.
Roche's (RHHBY) sBLA for Asthma Drug Xolair Accepted by FDA
by Zacks Equity Research
The FDA accepts Roche's (RHHBY) allergic asthma drug Xolair's sBLA for the treatment of nasal polyps in adult patients aged 18 years or above with inadequate response to intranasal corticosteroids.